Asolution Pharmaceuticals Private Limited - Due diligence report

A 360° intelligence report on Asolution Pharmaceuticals: trust score, financial health, credit view, compliance, directors, growth and distr…

2010-05-07 Mumbai, Maharashtra Active Unlisted Active Compliant
Share
View plans Plan
AP Asolution Pharmaceuticals Private Limited
View plans Plan
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹349 50% off New user
Or enjoy up to 50% off with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Asolution Pharmaceuticals — 360° Intelligence Report

Generated from MCA filings & public records
61/100
Trust Score
Moderate

Asolution Pharmaceuticals is assessed as Moderate with a Trust Score of 61/100. Asolution Pharmaceuticals is an active private limited indian non-government company incorporated in 2010, operating in the Pharma sector. The company has shown revenue growth across its recent filed years. It reported a loss in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and high financial risk profile.

Report generated on 14 Jul 2026 from the latest processed filings. Asolution Pharmaceuticals Private Limited snapshot & full profile →

Financial Health › Caution
Overall Assessment CautionWeakNeutralGoodStrong Good
Compliance › Strong

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreModerate
61/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
81/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreCaution Indicated
5/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreCaution Indicated
45/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
95/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
75/100
Revenue, profit, asset and hiring momentum.
Distress ScoreCaution Indicated
40/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 5 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 45/100 Caution Indicated
  • Liabilities ≈ 38% EBITDA - stretched.
  • Externally credit-rated (B+).

Charges position: 2 open (24.96 cr) · 4 satisfied (37.55 cr).

Banking relationships (from registered charges)
LenderChargesAmount
Others6 48.0 cr
Compliance Score: 81/100 Low Risk
  • Company status is Active as per MCA.
  • Balance sheet slightly behind (Mar 2024).
  • Litigation present in 1 court forum(s).
  • 1 active GST registration(s).
Legal cases on record (1)
05

Director Intelligence

Stability score: 95/100
NameDIN / PANDesignationAppointedTenureDIN status
NANDKUMAR KASHINATH CHODANKAR 01234567 Director 01/04/2018 6 yrs Approved
LAXMI NANDKUMAR CHODANKAR 01234567 Director 01/04/2018 6 yrs Approved
  • 2 directors on the board.
  • No disqualified or deactivated DINs.
  • Stable board - no exits in 3 years.
  • Average tenure above 5 years.
Director & KMP remuneration (FY 2021)
NameDesignationTotal remuneration
A K SharmaManaging Director2.4 cr
R MehtaWhole-time Director1.6 cr
S IyerCFO95.0 L

Remuneration is disclosed in the latest annual return. Unlock full report

06

Ownership & Group Intelligence

As per FY 2023 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
15 allotment(s) · 0 transfer(s)

Promoters hold a dominant controlling stake - exact percentages are part of the full report.

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 75 · Distress 40
Growth signals & trust indicators
Revenue acceleration: +1.42 over 4 year(s).
EPFO headcount growing - hiring signal.
Operating for 16+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
Revenue declined year-on-year.
Losses deepening year-on-year.
Negative net worth.
2 open charge(s) registered - assets are encumbered.
1 court case(s) on record - see the legal section for details.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence63/100
Review suggested
Suitability as a supplier / customer counterparty.
  • Statutory record is clean.
  • 3 distress signal(s) - see Risk Center.
  • Financial filings available for verification.
Banker assessment42/100
Enhanced diligence advised
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • 2 open charge(s) of 24.96 cr already registered.
  • Compliance record supports lending.
Investor view47/100
Mixed indicators
Growth quality and scalability through an investor lens.
  • 2 growth signal(s) detected.
  • Margin and return trends computable from filings.
  • Management team looks stable.
09

MCA Filings & Events Timeline

Latest 15 events
30 Sep 2024
Last AGM held
Annual general meeting
31 Mar 2024
Latest balance sheet
Filed with ROC
10 Jul 2023
Charge satisfied
Others
04 Jan 2023
Charge created
Others - 3.00 cr
03 Aug 2022
Charge satisfied
Others
29 Jan 2022
Charge created
Others - 42.04 Lakh
18 Aug 2020
Charge created
Others - 3.47 cr
06 Jun 2020
Charge created
Others - 60.00 Lakh
18 Jul 2017
Securities allotted
75000 Preference Shares - 75.00 Lakh raised
27 Jun 2017
Securities allotted
75000 Preference Shares - 75.00 Lakh raised
24 May 2017
Securities allotted
100000 Preference Shares - 1.00 cr raised
08 May 2017
Securities allotted
40000 Preference Shares - 40.00 Lakh raised
27 Apr 2017
Securities allotted
35000 Preference Shares - 35.00 Lakh raised
28 Mar 2017
Securities allotted
240000 Equity Shares - 2.23 cr raised
23 Mar 2017
Securities allotted
60000 Equity Shares - 55.80 Lakh raised
10

Key Observations

Auto-generated from the data above
Revenue grew 2.1x over the last 4 financial year(s).
Net profit margin moved from 24% to 0.86.
Compliance record is strong - status, filings and flags are clean.
2 active director(s) / partner(s); board looks stable and experienced.
1 active GST registration(s) indicate ongoing business operations.
Carries an external credit rating of B+ from Icra.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a dominant controlling stake as per the FY 2023 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 15 security allotment(s) - amounts available in the full report.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Mac Labs U74999TG2018PLC128275 Hyderabad, Telangana, India
Adifab Industries Private Limited U24304MH2017PTC294378 Panvel, Maharashtra, India
Vikas Laboratories Private Limited U24240MH2000PTC129376 Mumbai, Maharashtra, India
Padarsh Pharmaceuticals Private Limited U45200MH1981PTC025361 Mumbai, Maharashtra, India
Octet Chemicals Private Limited U24290TG2020PTC141494 Secunderabad, Telangana, India
Jaywin Remedies Private Limited U24231GJ1988PTC010605 Ahmedabad, Gujarat, India
Savvy Care & Cosmetics Private Limited U24239MH2006PTC165548 Navi Mumbai, Maharashtra, India
Aarmonia Chemicals Private Limited U24100MH2010PTC205526 Mumbai, Maharashtra, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Asolution Pharmaceuticals before audits and certifications: compliance score 81/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Asolution Pharmaceuticals: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Enhanced diligence advised. Credit risk score 45/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Mixed indicators. Growth score 75/100, margin trends, ownership structure and peer set for Asolution Pharmaceuticals - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Review suggested. Trust score 61/100, distress signals and MSME payment-delay disclosures - know whether Asolution Pharmaceuticals pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (1 case(s) on record), regulatory flags, charge documents trail and director networks for Asolution Pharmaceuticals - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Asolution Pharmaceuticals an active company?

Asolution Pharmaceuticals has MCA status “Active” with a compliance score of 81/100 (Low Risk).

Is Asolution Pharmaceuticals financially healthy?

Asolution Pharmaceuticals has a Financial Health Score of 5/100 (Caution Indicated) based on its filed financial statements.

Should I do business with Asolution Pharmaceuticals?

Its overall Trust Score is 61/100 (Moderate). Vendor verdict: Review suggested. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Asolution Pharmaceuticals?

Promoters hold a dominant controlling stake - exact percentages are in the full report. 2 active director(s) are on record.

Does Asolution Pharmaceuticals have loans or charges against its assets?

2 open charge(s) are registered against its assets, and 4 earlier charge(s) stand satisfied.

Is Asolution Pharmaceuticals up to date with its ROC filings?

Balance sheet slightly behind (Mar 2024). Overall compliance score: 81/100 (Low Risk).

Is it risky to lend to Asolution Pharmaceuticals?

Its Credit Risk Score is 45/100 (Caution Indicated). Banker verdict: Enhanced diligence advised.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.